Resverlogix Corp.

  • Calgary, Alberta

Headcount: 35 employees

  • Biotechnology
  • Healthcare Facility

Organization Profile

Resverlogix Corp. (TSX:RVX) is a clinical stage biotechnology company developing compounds involving ApoA-I production. RVX-208 is a first-in-class small molecule in development for the treatment of diseases such as atherosclerosis, Diabetes Mellitus and Alzheimer’s disease. RVX-208 is the first BET bromodomain inhibitor in clinical trials. Resverlogix's common shares trade on the Toronto Stock Exchange (TSX: RVX). For further information please visit We can be followed on our blog at

Contact Information

Bradd Cann
Chief Financial Officer
Tel: (403)254-9252

Latest News Releases